Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-17-041470
Filing Date
2017-06-22
Accepted
2017-06-22 19:21:57
Documents
2
Period of Report
2017-06-22

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 5834
2 POA DOCUMENT poa.txt EX-24.4_732831 4391
  Complete submission text file 0001209191-17-041470.txt   11563
Mailing Address C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949
Business Address
Ekman Lars (Reporting) CIK: 0001376117 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36276 | Film No.: 17926100

Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Issuer) CIK: 0001515673 (see all company filings)

EIN.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations